Aug 5, 2026 04:00PM
Jul 8, 2026 08:00AM
Jul 8, 2026 08:00AM
May 6, 2026 04:00PM
Feb 25, 2026 04:00PM
Jan 12, 2026 08:10AM
Jan 12, 2026 08:00AM Arcutis Highlights 2026 Strategic Priorities and Anticipated Milestones
Nov 17, 2025 08:04AM
Nov 17, 2025 08:00AM
Aug 6, 2025 04:00PM
Jun 26, 2025 08:00AM
Jun 10, 2025 08:00AM
Jun 9, 2025 06:40AM
Jun 6, 2025 08:00AM Arcutis to Present New Long-Term Results of ZORYVE® (roflumilast) Cream at the 2025 Revolutionizing Atopic Dermatitis Conference
May 7, 2025 11:19AM
May 7, 2025 11:18AM
May 6, 2025 04:00PM
Mar 7, 2025 08:00AM
Feb 28, 2025 09:00AM
Feb 26, 2025 08:02AM
Feb 26, 2025 08:00AM U.S. FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis 
Feb 25, 2025 04:00PM
Nov 6, 2024 04:00PM
Sep 24, 2024 08:00AM
Sep 24, 2024 08:00AM
Jul 9, 2024 08:43AM
Jul 9, 2024 08:00AM
Jun 10, 2024 02:31PM Arcutis Biotherapeutics (ARQT) Announces New Long-Term Data of Roflumilast Cream 0.15%
Jun 10, 2024 02:30PM
May 15, 2024 07:15AM
May 14, 2024 04:00PM
Mar 10, 2024 04:00PM
Feb 27, 2024 05:50AM
Jan 16, 2024 05:19AM
Jan 14, 2024 04:00AM Majority of Individuals with Atopic Dermatitis Improved with Arcutis’ Roflumilast Cream 0.15% According to New Data from Phase 3 Program
Nov 29, 2023 08:02AM
Nov 29, 2023 08:00AM
Apr 18, 2023 08:02AM
Apr 18, 2023 08:00AM
Apr 18, 2023 08:00AM
Jul 7, 2022 06:15AM
Jun 6, 2022 08:41AM STRATUM Data is "Clearly Good News... Could Drive Stock Higher" - Cantor Fitzgerald Bullish on Arcutis Biotherapeutics (ARQT) Following Phase 3 Readout
Jun 6, 2022 07:30AM
Jun 6, 2022 07:30AM
Jun 6, 2022 07:30AM
May 5, 2022 04:01PM
May 5, 2022 04:01PM
Mar 28, 2022 10:28AM
Mar 28, 2022 08:00AM Arcutis Highlights Growth Opportunities at Investor Day in Advance of 2022 Catalysts
Mar 28, 2022 08:00AM

15,661 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All